Neuroendocrine tumors in the ovary: histogenesis, pathologic differentiation, and clinical presentation

Vora, Moiz; Lacour, Robin A.; Black, Destin; Turbat‐Herrera, Elba A.; Gu, Xin

doi:10.1007/s00404-015-3865-0

Cited by 29 publications

(48 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…First, the neuroendocrine cells appearing in normal ovarian epithelium tissue, borderline, or malignant ovary tumor serve as a 'seed' and potentially develop into neuroendocrine carcinoma of the ovary. Second, neuroendocrine carcinoma of the ovary may differentiate from other non-neuroendocrine cells, which contain mutational genes that can facilitate neuroendocrine transition 4 15 16. Pathologic diagnoses for neuroendocrine carcinoma of the ovary can be difficult because the neuroendocrine tumors express similar biomarkers, such as synaptophysin, chromogranin, and CD56, and have different origin sites and histological subtypes 6 17.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Clinicopathologic characteristics and survival outcomes in neuroendocrine carcinoma of the ovary

Zhu

Meng

Fang

et al. 2019

Int J Gynecol Cancer

View full text Add to dashboard Cite

ObjectiveNeuroendocrine tumors are rare in the ovary. Definitive epidemiologic and prognostic information for neuroendocrine carcinoma of the ovary is lacking. This retrospective population-based study aimed to elucidate the demographic and clinicopathologic characteristics of neuroendocrine carcinoma of the ovary.MethodsPatients with neuroendocrine carcinoma of the ovary diagnosed between January 1994 and December 2014were identified from the Surveillance, Epidemiology, and End Results (SEER) database of the National Cancer Institute. Cancer-specific survival was calculated by Kaplan-Meier plots and comparisons were performed using the log-rank test. A Cox hazard regression analysis was performed to identify independent predictors of cancer-specific survival in patients with neuroendocrine carcinoma of the ovary.ResultsA total of 166 patients were included, and 21.1% were younger than 50 years old. The majority of patients (59.6%) presented with unilateral tumors. Patients with neuroendocrine carcinoma of the ovary had significantly worse survival compared with most subtypes of epithelial ovarian cancer (including serous, endometrioid, mucinous, and clear cell), and similar to ovarian carcinosarcoma. The rate of cancer-specific survival was significantly different under the SEER histologic stages. Patients with low-grade neuroendocrine carcinoma of the ovary had longer average survival times than those with high-grade neuroendocrine carcinoma of the ovary (HR 3.43, 95% CI 1.56 to 7.54, p=0.002). Patients with neuroendocrine carcinoma of the ovary who underwent surgery had significantly better survival than those who did not undergo surgery (HR 2.23; 95% CI 1.45 to 3.43, p=<0.05).ConclusionsEarly clinical stage and low tumor grade independently predict better survival in patients with neuroendocrine carcinoma of the ovary. Surgery may be a useful therapy for neuroendocrine carcinoma of the ovary.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Chromogranin A is also sometimes used as a biochemical marker for diagnosis of neuroendocrine tumors 20. Radiologic examination, including computed tomography and magnetic resonance imaging, as an early detection modality for precision diagnosis and antidiastole of neuroendocrine carcinoma of the ovary also show non-specific findings 16…”

Section: Discussionmentioning

confidence: 99%

Clinicopathologic characteristics and survival outcomes in neuroendocrine carcinoma of the ovary

Zhu

Meng

Fang

et al. 2019

Int J Gynecol Cancer

View full text Add to dashboard Cite

show abstract

“…LCNECs have been found in many organs, including the lung, stomach, uterus, ovary, and bladder [ 11 – 14 ]. Genomic profiling using a hybrid capture based assay revealed multiple alterations including CD274 (PD-L1) amplification, MYC amplification, TP53 mutation, RB1 loss, and mutations in the APC and STK11 (LKB) genes.…”

Section: Conclusion and Discussionmentioning

confidence: 99%

Checkpoint inhibitor is active against large cell neuroendocrine carcinoma with high tumor mutation burden

Wang¹,

Urisman²,

Albacker³

et al. 2017

j. immunotherapy cancer

View full text Add to dashboard Cite

BackgroundLarge cell neuroendocrine tumor (LCNEC) of the lung is a rare and aggressive tumor similar to small cell lung cancer (SCLC). Thus, it is often treated similarly to SCLC in the front-line setting with a platinum doublet. However, treatment for patients beyond the first line remains undefined.Case presentationWe report the case of a patient with stage IB LCNEC (PD-L1 negative but positive for PD-L1 amplification and tumor mutation burden high) who progressed after adjuvant chemotherapy after surgery and subsequent therapy with an antibody drug conjugate targeting a neuroendocrine-specific cell surface marker but achieved a significant and durable response with pembrolizumab, a humanized IgG4 monoclonal anti-PD-1 antibody.ConclusionsImmunotherapy with checkpoint inhibitors is an effective treatment option for patients with metastatic LCNEC, even if PD-L1 expression is negative.

show abstract

“…There are only a few case reports describing primary ovarian carcinoid tumors with aggressive histology such as a loss of the neuroendocrine growth pattern, frequent mitotic figures, and foci of coagulative tumor necrosis ( Kim et al, 2015 ) ( Vora et al, 2016 ). A new targeting agent that affects the mammalian target of rapamycin (mTOR) pathway has been used to treat advanced NETs ( Chan and Kulke, 2014 ) ( Cives and Strosberg, 2017 ).…”

Section: Introductionmentioning

confidence: 99%

Aggressive neuroendocrine tumor of the ovary with multiple metastases treated with everolimus: A case report

Kaiho-Sakuma

Toyoshima

Watanabe

et al. 2018

Gynecologic Oncology Reports

View full text Add to dashboard Cite

show abstract

Neuroendocrine tumors in the ovary: histogenesis, pathologic differentiation, and clinical presentation

Cited by 29 publications

References 23 publications

Clinicopathologic characteristics and survival outcomes in neuroendocrine carcinoma of the ovary

Clinicopathologic characteristics and survival outcomes in neuroendocrine carcinoma of the ovary

Checkpoint inhibitor is active against large cell neuroendocrine carcinoma with high tumor mutation burden

Aggressive neuroendocrine tumor of the ovary with multiple metastases treated with everolimus: A case report

Contact Info

Product

Resources

About